Latest Patent Protection News

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

Cann Group Limited has extended the expiry of its NAB debt facilities by two weeks, providing a brief but vital window to advance its refinancing plans.

Syntara Limited has reported positive final data from its Phase 2a trial of amsulostat in myelofibrosis, demonstrating significant symptom relief and spleen volume reduction with a favorable safety profile. These results pave the way for advancing clinical development and partnership discussions.

Hazer Group has been granted a pivotal patent in Singapore for its proprietary graphite morphology process, reinforcing its foothold in Southeast Asia's clean energy and advanced manufacturing markets.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

Synertec Corporation has secured another order from Santos Limited for its Powerhouse renewable microgrid system at a remote Queensland gas site, reinforcing its role in decarbonising industrial energy supply.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.